- Home
- HGTY vs TERN Comparison
HGTY vs TERN Comparison
Compare HGTY & TERN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HGTY
- TERN
- Stock Information
- Founded
- HGTY 1984
- TERN 2017
- Country
- HGTY United States
- TERN United States
- Employees
- HGTY N/A
- TERN N/A
- Industry
- HGTY Specialty Insurers
- TERN Biotechnology: Pharmaceutical Preparations
- Sector
- HGTY Finance
- TERN Health Care
- Exchange
- HGTY Nasdaq
- TERN Nasdaq
- Market Cap
- HGTY 938.5M
- TERN 811.4M
- IPO Year
- HGTY N/A
- TERN 2021
- Fundamental
- Price
- HGTY $10.66
- TERN $7.50
- Analyst Decision
- HGTY Hold
- TERN Strong Buy
- Analyst Count
- HGTY 2
- TERN 5
- Target Price
- HGTY $11.00
- TERN $15.90
- AVG Volume (30 Days)
- HGTY 52.2K
- TERN 1.3M
- Earning Date
- HGTY 11-06-2024
- TERN 11-12-2024
- Dividend Yield
- HGTY N/A
- TERN N/A
- EPS Growth
- HGTY N/A
- TERN N/A
- EPS
- HGTY 0.11
- TERN N/A
- Revenue
- HGTY $1,105,550,000.00
- TERN N/A
- Revenue This Year
- HGTY $20.27
- TERN N/A
- Revenue Next Year
- HGTY $16.13
- TERN N/A
- P/E Ratio
- HGTY $99.72
- TERN N/A
- Revenue Growth
- HGTY 23.75
- TERN N/A
- 52 Week Low
- HGTY $7.52
- TERN $3.26
- 52 Week High
- HGTY $12.35
- TERN $11.40
- Technical
- Relative Strength Index (RSI)
- HGTY 46.30
- TERN 38.90
- Support Level
- HGTY $10.33
- TERN $7.40
- Resistance Level
- HGTY $10.91
- TERN $7.84
- Average True Range (ATR)
- HGTY 0.26
- TERN 0.42
- MACD
- HGTY 0.04
- TERN -0.10
- Stochastic Oscillator
- HGTY 72.53
- TERN 13.79
About HGTY Hagerty Inc.
Hagerty Inc is a provider of specialty automotive insurance. The company underwrites, sells, and services classic car and enthusiast vehicle insurance policies. Substantial revenue is derived from Commission and fees. Geographically it serves Europe, Canada, and the United States.
About TERN Terns Pharmaceuticals Inc.
Terns Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. The company is developing a portfolio of small-molecule single-agent and combination therapy candidates for the treatment of non-alcoholic steatohepatitis, NASH, and other chronic liver diseases.